Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead

COVID-19 Antibody Bamlanivimab Fails In Sicker Patients

 
• By Joseph Haas
  
US-Money-and-Pills_V2_1200x675
Lilly's revenue is growing despite the pandemic, but not without COVID-19-related headwinds
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business